Replies to post #124686 on NorthWest Biotherapeutics Inc (NWBO)

[791branko]

Flipper44 & RKmatters,

I recognize there are many differences between Stupp's and NWBO's patient populations both on the plus and minus sides of affecting survival.
Given all the differences I still think using Stupp's curve as an estimate for NWBO's control arm is far better than using UCLA's curve.
UCLA's survival curve looks too strong in fact it tracks loosely with Stupp's MGMT methylated patients which is the best GBM survivors sub-group. This sub-group includes the longest-living psPD patients which should not make it into NWBO's trial.

Here's a survival competitor chart I put together for reference -